Literature DB >> 11495935

Paradoxical reduction of synaptic inhibition by vigabatrin.

L S Overstreet1, G L Westbrook.   

Abstract

GABAergic inhibition, a primary target for pharmacological modulation of excitability in the CNS, can be altered by multiple mechanisms including alteration of GABA metabolism. Gamma-vinyl GABA (vigabatrin, GVG) is an irreversible inhibitor of the GABA catabolic enzyme GABA transaminase, thus its anticonvulsant properties are thought to result from an elevation of brain GABA levels. We examined the effects of GVG on GABAergic synaptic transmission in hippocampal slices. GVG unexpectedly reduced miniature and evoked inhibitory postsynaptic currents (IPSCs) in dentate granule cells. The reduction in synaptic events was accompanied by an increase in tonic GABA(A) receptor-mediated current. These effects developed slowly and persisted following wash out of GVG. The GVG pretreatment reduced sucrose-evoked GABA release as well as postsynaptic sensitivity to exogenous GABA, indicating that both pre- and postsynaptic mechanisms contributed to the reduction in synaptic currents. These results suggest that tonic rather than phasic increases in GABA underlie the anticonvulsant properties of GVG, and that mechanisms that elevate brain neurotransmitter levels do not necessarily correlate with enhanced synaptic release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495935     DOI: 10.1152/jn.2001.86.2.596

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  31 in total

1.  Synapse density regulates independence at unitary inhibitory synapses.

Authors:  Linda S Overstreet; Gary L Westbrook
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors.

Authors:  Brandon M Stell; Stephen G Brickley; C Y Tang; Mark Farrant; Istvan Mody
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

3.  Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus.

Authors:  David E Naylor; Hantao Liu; Claude G Wasterlain
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

4.  In the developing rat hippocampus a tonic GABAA-mediated conductance selectively enhances the glutamatergic drive of principal cells.

Authors:  Ivan Marchionni; Azar Omrani; Enrico Cherubini
Journal:  J Physiol       Date:  2007-02-22       Impact factor: 5.182

5.  Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1.

Authors:  Yuanming Wu; Wengang Wang; Ana Díez-Sampedro; George B Richerson
Journal:  Neuron       Date:  2007-12-06       Impact factor: 17.173

6.  Modulation of spontaneous and GABA-evoked tonic alpha4beta3delta and alpha4beta3gamma2L GABAA receptor currents by protein kinase A.

Authors:  Xin Tang; Ciria C Hernandez; Robert L Macdonald
Journal:  J Neurophysiol       Date:  2009-11-25       Impact factor: 2.714

7.  GABA regulates synaptic integration of newly generated neurons in the adult brain.

Authors:  Shaoyu Ge; Eyleen L K Goh; Kurt A Sailor; Yasuji Kitabatake; Guo-li Ming; Hongjun Song
Journal:  Nature       Date:  2005-12-11       Impact factor: 49.962

8.  Input-specific GABAergic signaling to newborn neurons in adult dentate gyrus.

Authors:  Sean J Markwardt; Jacques I Wadiche; Linda S Overstreet-Wadiche
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

9.  SSADH deficiency leads to elevated extracellular GABA levels and increased GABAergic neurotransmission in the mouse cerebral cortex.

Authors:  K R Drasbek; I Vardya; M Delenclos; K M Gibson; K Jensen
Journal:  J Inherit Metab Dis       Date:  2008-08-15       Impact factor: 4.982

Review 10.  Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABAA receptors as an opportunity for drug development?

Authors:  M Wallner; R W Olsen
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.